API
< Back to all clusters
[HEALTH] · United States · 9 sources

started · updated

FDA requires GLP-1 medication warnings for rare eye condition

The U.S. Food and Drug Administration (FDA) has announced that manufacturers of GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, must update warning labels to address the risk of non-arteritic anterior ischemic optic neuropathy (NAION).

NAION is a rare condition characterized by sudden, painless, and potentially permanent vision loss, sometimes referred to as an eye stroke. While studies have identified an association between GLP-1 medications and NAION, researchers have not established direct causation.

FDA analysis found that the incidence rate of NAION in patients treated with GLP-1s was 6.4 cases per 100,000 person-years, compared to 3.8 cases per 100,000 person-years in groups receiving placebos or other glucose-lowering medications.

Entities

Aon · Association of Generic Drug Users · CagriSema · Eli Lilly · European Medicines Agency · Food and Drug Administration · Mounjaro · National Supplementary Health Agency · Novo Nordisk · Ozempic · U.S. Food and Drug Administration · Wegovy

Claims

What the coverage asserts, and how many sources carry each claim.

  • [○ 1 SOURCE] Patients using 1 mg and 1.7 mg doses of CagriSema saw an average weight reduction of 21% after 68 weeks.
  • [○ 1 SOURCE] Medical costs in Brazil are projected to rise by 11.1% in 2027.
  • [○ 1 SOURCE] GLP-1 medications account for between 1% and 10% of medical cost trends in some markets.
  • [○ 1 SOURCE] Patients are suing Novo Nordisk and Eli Lilly alleging they were not adequately warned about risks. www.lanacion.com.ar
  • [○ 1 SOURCE] The EMA is investigating the inclusion of information about NAION for Mounjaro and Trulicity. observador.pt
  • [○ 1 SOURCE] The FDA has requested manufacturers to update safety warnings for GLP-1 agonists regarding the risk of NAION. www.notiziariochimicofarmaceutico.it
  • [○ 1 SOURCE] NAION is characterized by sudden vision loss in one eye, often occurring upon waking. www.notiziariochimicofarmaceutico.it
  • [○ 1 SOURCE] CagriSema is a combination of cagrilintide and semaglutide.
  • [● 2 SOURCES] The FDA announced that GLP-1 manufacturers must update warning labels to address the risk of NAION. ankinlaw.com · www.newswise.com
  • [○ 1 SOURCE] Studies identified an association between GLP-1 medications and NAION, but did not establish direct causation. www.newswise.com
  • [○ 1 SOURCE] The incidence rate of NAION was 6.4 cases per 100,000 person-years in patients treated with GLP-1s. www.newswise.com
  • [○ 1 SOURCE] Two patients reportedly developed psychiatric symptoms after abruptly stopping tirzepatide. dominicanaaldia.com